Foro acciones Island Pharmaceuticals Ltd

Recomendaciones de Island Pharmaceuticals Ltd

El lugar donde dejar tu recomendación de Island Pharmaceuticals Ltd para que otros accionistas o interesados vean tu valoración.

Preguntas frecuentes de Island Pharmaceuticals Ltd

Aquí vamos añadiendo las preguntas frecuentes que se hacen los accionistas de Island Pharmaceuticals Ltd.

Perfil de Island Pharmaceuticals Ltd

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing approximately four and a half thousand molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was founded in 2017 and is based in Camberwell, Australia.

Información de contacto

• Teléfono: 61370367675
• Web: www.islandpharmaceuticals.com
• Dirección: 697 Burke Road, Suite 201
• Ciudad: Camberwell
• País: Australia